{"title":"胰高血糖素样肽-1受体激动剂对肾脏参数的影响：随机对照试验的荟萃分析","authors":"Wenjing Li, Xiaoyan Liang, Na Sun, Daqing Zhang","doi":"10.1186/s12902-025-01948-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To verify the influence of glucagon-like peptide-1 receptor agonists (GLP-1 RA) on renal function parameters in type 2 diabetes based on well-known randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>PubMed, Cochrane, Web of Science, Embase, and grey literature were searched for RCTs published until December 24, 2024. The quality of the RCTs was assessed using the Cochrane risk-of-bias tool. Weighted mean differences (WMD) and 95% confidence intervals (CIs) were calculated for continuous variables using meta-analysis. The primary outcomes were composite renal function parameters, including serum creatinine (Cr) levels, estimated glomerular filtration rate (eGFR), urinary albumin excretion (UAE), and urinary albumin-to-creatinine ratio (UACR).</p><p><strong>Results: </strong>Pooled data from 24 studies revealed that GLP-1 RA positively influenced renal outcomes in the type 2 diabetes group to some extent compared with that in the control group. GLP- 1 RA decreased serum creatinine levels (WMD=-0.10, 95%CI -0.19 to -0.01, I<sup>2</sup> = 33%, P < 0.05), eGFR(WMD = 0.54, 95% CI 0.19 to 0.90, I<sup>2</sup> = 27%, P < 0.05), UAE (WMD=-11.92, 95% CI - 23.50 to - 0.33, I<sup>2</sup> = 0%, P < 0.05) and UACR (WMD: -1.01 mg/g, 95% CI:-1.68, -0.34, I<sup>2</sup> = 15%, P < 0.05) in the type 2 diabetes group.</p><p><strong>Conclusion: </strong>GLP-1 RA treatment significantly elevated eGFR, decreased the UACR, and positively influenced renal function outcomes in the type 2 diabetes group.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"124"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056997/pdf/","citationCount":"0","resultStr":"{\"title\":\"Influence of glucagon-like peptide-1 receptor agonists on renal parameters: a meta-analysis of randomized controlled trials.\",\"authors\":\"Wenjing Li, Xiaoyan Liang, Na Sun, Daqing Zhang\",\"doi\":\"10.1186/s12902-025-01948-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>To verify the influence of glucagon-like peptide-1 receptor agonists (GLP-1 RA) on renal function parameters in type 2 diabetes based on well-known randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>PubMed, Cochrane, Web of Science, Embase, and grey literature were searched for RCTs published until December 24, 2024. The quality of the RCTs was assessed using the Cochrane risk-of-bias tool. Weighted mean differences (WMD) and 95% confidence intervals (CIs) were calculated for continuous variables using meta-analysis. The primary outcomes were composite renal function parameters, including serum creatinine (Cr) levels, estimated glomerular filtration rate (eGFR), urinary albumin excretion (UAE), and urinary albumin-to-creatinine ratio (UACR).</p><p><strong>Results: </strong>Pooled data from 24 studies revealed that GLP-1 RA positively influenced renal outcomes in the type 2 diabetes group to some extent compared with that in the control group. GLP- 1 RA decreased serum creatinine levels (WMD=-0.10, 95%CI -0.19 to -0.01, I<sup>2</sup> = 33%, P < 0.05), eGFR(WMD = 0.54, 95% CI 0.19 to 0.90, I<sup>2</sup> = 27%, P < 0.05), UAE (WMD=-11.92, 95% CI - 23.50 to - 0.33, I<sup>2</sup> = 0%, P < 0.05) and UACR (WMD: -1.01 mg/g, 95% CI:-1.68, -0.34, I<sup>2</sup> = 15%, P < 0.05) in the type 2 diabetes group.</p><p><strong>Conclusion: </strong>GLP-1 RA treatment significantly elevated eGFR, decreased the UACR, and positively influenced renal function outcomes in the type 2 diabetes group.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>\",\"PeriodicalId\":9152,\"journal\":{\"name\":\"BMC Endocrine Disorders\",\"volume\":\"25 1\",\"pages\":\"124\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056997/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Endocrine Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12902-025-01948-7\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Endocrine Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12902-025-01948-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
目的：通过知名的随机对照试验（RCTs）验证胰高血糖素样肽-1受体激动剂（GLP-1 RA）对2型糖尿病患者肾功能参数的影响。方法：检索PubMed、Cochrane、Web of Science、Embase和灰色文献，检索截止到2024年12月24日发表的rct。使用Cochrane风险偏倚工具评估随机对照试验的质量。使用meta分析计算连续变量的加权平均差（WMD）和95%置信区间（ci）。主要结局是综合肾功能参数，包括血清肌酐（Cr）水平、肾小球滤过率（eGFR）、尿白蛋白排泄（UAE）和尿白蛋白/肌酐比值（UACR）。结果：24项研究的汇总数据显示，与对照组相比，GLP-1 RA对2型糖尿病组的肾结局有一定程度的积极影响。GLP-1 RA降低血清肌酐水平（WMD=-0.10, 95%CI为-0.19 ~ -0.01,I2 = 33%, P 2 = 27%, P 2 = 0%, P 2 = 15%， P）结论：GLP-1 RA治疗可显著提高2型糖尿病组eGFR，降低UACR，对肾功能结局有积极影响。临床试验号：不适用。
Influence of glucagon-like peptide-1 receptor agonists on renal parameters: a meta-analysis of randomized controlled trials.
Aims: To verify the influence of glucagon-like peptide-1 receptor agonists (GLP-1 RA) on renal function parameters in type 2 diabetes based on well-known randomized controlled trials (RCTs).
Methods: PubMed, Cochrane, Web of Science, Embase, and grey literature were searched for RCTs published until December 24, 2024. The quality of the RCTs was assessed using the Cochrane risk-of-bias tool. Weighted mean differences (WMD) and 95% confidence intervals (CIs) were calculated for continuous variables using meta-analysis. The primary outcomes were composite renal function parameters, including serum creatinine (Cr) levels, estimated glomerular filtration rate (eGFR), urinary albumin excretion (UAE), and urinary albumin-to-creatinine ratio (UACR).
Results: Pooled data from 24 studies revealed that GLP-1 RA positively influenced renal outcomes in the type 2 diabetes group to some extent compared with that in the control group. GLP- 1 RA decreased serum creatinine levels (WMD=-0.10, 95%CI -0.19 to -0.01, I2 = 33%, P < 0.05), eGFR(WMD = 0.54, 95% CI 0.19 to 0.90, I2 = 27%, P < 0.05), UAE (WMD=-11.92, 95% CI - 23.50 to - 0.33, I2 = 0%, P < 0.05) and UACR (WMD: -1.01 mg/g, 95% CI:-1.68, -0.34, I2 = 15%, P < 0.05) in the type 2 diabetes group.
Conclusion: GLP-1 RA treatment significantly elevated eGFR, decreased the UACR, and positively influenced renal function outcomes in the type 2 diabetes group.
期刊介绍：
BMC Endocrine Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of endocrine disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
